Drug Profile
3K3A-APC
Alternative Names: 3K3A-activated protein C; 3K3A-APC non-anticoagulant mutant - ZZ Biotech; Activated-protein-C-analogue-University-of-Southern-California/Scripps-Research-Institute/ZZ-Biotech; Human-recombinant-3K3A-APC; Recombinant variant of human activated protein C (3K3A-APC)-ZZ-BiotechLatest Information Update: 21 Sep 2023
Price :
$50
*
At a glance
- Originator Socratech; The Scripps Research Institute; University of Southern California
- Developer Socratech; The Scripps Research Institute; University of Southern California; ZZ Biotech
- Class Anti-infectives; Anti-inflammatories; Antithrombotics; Blood proteins; Enzyme precursors; Foot disorder therapies; Recombinant proteins; Serine endopeptidases; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Activated protein C receptor modulators; Factor V inhibitors; Factor VIII inhibitors; PAR 1 receptor modulators; PAR-3 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis; Stroke
- Phase I Diabetic foot ulcer
- No development reported Neurological disorders; Septic shock
Most Recent Events
- 19 Sep 2023 Phase-I clinical trials in Diabetic foot ulcer in USA (Topical) (ZZ Biotech pipeline, September 2023)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (IV)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA (IV)